Catheter-Directed Thrombolysis vs. Anticoagulation in Deep Vein Thrombosis: A Comparative Study
Authors:
- Mehmet Cahit SaricaogluMSMehmet Cahit Saricaoglu
- Ali Ihsan HasdeAHAli Ihsan Hasde
- Ali Fuat KaracuhaAKAli Fuat Karacuha
- Ahmet KayanAKAhmet Kayan
- Onur BuyukcakırOBOnur Buyukcakır
- Fatma AkcaFAFatma Akca
- Evren OzcinarEOEvren Ozcinar
- Cagdas BaranCagdas Baran
- Mustafa Bahadir InanMIMustafa Bahadir Inan
- Mustafa SirlakMSMustafa Sirlak
- Levent YaziciogluLYLevent Yazicioglu
- Ahmet Ruchan AkarAAAhmet Ruchan Akar
Open Access
- 9 May 2025
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (10) , 3298
Abstract
Background: Deep vein thrombosis (DVT) is an important component of venous thromboembolism and can lead to pulmonary embolism with high morbidity and mortality. Anticoagulant therapy alone (AC) and catheter-directed thrombolysis (CDT) are commonly used strategies for the management of DVT. Although CDT has been reported to be effective in reducing the risk of post-thrombotic syndrome (PTS), it remains unclear in which patient groups it should be preferred due to the risk of bleeding. Methods: This retrospective study included 175 patients diagnosed with DVT between 2015 and 2024 (98 AC, 77 CDT). Patients with a diagnosis of proximal DVT, aged ≥18 years, and with at least 30 days of follow-up data were included. The primary endpoint was 30-day mortality and secondary endpoints were the length of hospitalization, pulmonary embolism, and bleeding complications. Results: The CDT group was superior to AC in thrombus clearance rates, especially in iliac vein thrombosis (97.7% vs. 78%, p = 0.003). Clinical symptoms improved faster in the CDT group, but total hospitalization was longer. There were no significant differences in bleeding complications and mortality rates between the two groups. Conclusions: The optimal approach to DVT treatment should be based on the patient’s individual risk factors. Although CDT provides a higher thrombus clearance rate, especially in iliac vein thrombosis, it may not be suitable for all patients. Future large-scale studies will contribute to a better understanding of the long-term outcomes of interventional therapies.Keywords
All Related Versions
This publication has 20 references indexed in Scilit:
- Rationale and design of the DEFIANCE study: A randomized controlled trial of mechanical thrombectomy versus anticoagulation alone for iliofemoral deep vein thrombosisAmerican Heart Journal, 2024
- Antithrombotic Therapy for VTE DiseaseChest, 2024
- Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous ThrombosisEuropean Journal of Vascular and Endovascular Surgery, 2021
- 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)European Heart Journal, 2019
- The Attract Trial: A Step Forward for Evidence Based DVT CareEuropean Journal of Vascular and Endovascular Surgery, 2018
- Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein ThrombosisNew England Journal of Medicine, 2017
- Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trialThe Lancet Haematology, 2016
- Comparative Outcomes of Catheter-Directed Thrombolysis Plus Anticoagulation vs Anticoagulation Alone to Treat Lower-Extremity Proximal Deep Vein ThrombosisJAMA Internal Medicine, 2014
- Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trialThe Lancet, 2012
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005